Diabetes Update: Facts, Trends and Observations

Diabetes Update
Facts, Trends and Observations
Bruce Bode, MD, FACE Atlanta Diabetes Associates
Ultimate Goals Of Diabetes Treatment

Sustained Normal Blood Glucose Control
= =
No Long Term Diabetes Complications No Acute Diabetes Complications
Lowest Incidence of Hypoglycemia
Best Quality of Life with a Chronic Disease
Relative Risk of Progression of Diabetic Complications

15 13 Retinop Neph Neurop
RELATIVE RISK
11 9 7 5 3 1 6 7 8 9 10 11 12
Mean A1C
DCCT Research Group, N Engl J Med 1993, 329:977986.
Lifetime Benefits of Intensive Therapy (DCCT)

Gain of 15.3 years of complication free living compared to conventional therapy
Gain of 5.1 years of life compared to conventional therapy
DCCT Study Group, JAMA 1996, 276:1409-1415.
DCCT
10% reduction in HbA1c 43% reduced risk of retinopathy progression 18% increased risk of severe hypoglycemia with coma and/or seizure
DCCT Research Group, N Engl J Med 1993, 329:977986.
Lowering A1C Reduces Risk of Complications

United Kingdom Prospective Diabetes Study (UKPDS)
Reduction in risk (%)*
0
-10 -20 -30 -40 -50
*Percent risk reduction per 0.9% decrease in HbA1C; UKPDS. Lancet. 1998;352:837-853.
Any diabetesrelated endpoint

-12
p=0.029
-16
p=0.052 -21
Microvascular endpoint
-25
p=0.0099
p=0.015
MI
-34
Retinopathy Albuminuria at 12 years
p=0.000054
New Targets of Intensive Diabetes Management

Near-normal glycemia A1C less than 6.5% Post-prandial: <140 mg/dl Avoid short-term crisis Hypoglycemia Hyperglycemia DKA Minimize long-term complications Improve QOL
ADA: Clinical Practice Recommendations, 2001. AACE and EASD DCCT Research Group, N Engl J Med 1993, 329:977-986.
How Are We Doing?
U.S. Diabetes Prevalence

Diabetes kills 1 American every 3 minutes
18 Million
New case diagnosed every 40 seconds More deaths than AIDS and breast cancer combined Average life expectancy: 15 years less than nondiabetes population Afflicts over 177 million people worldwide 300 million afflicted by 2025
World View
177 million worldwide 4th leading cause of death by disease India 33 million people with diabetes China 23 million people with diabetes Population of diabetes will double to triple by 2025 One out of every three Americans born today will develop diabetes
Time magazine December 2003; CDC
Costs Continue to Increase (U.S.)

$240
$192
$200
$156
$160
$109
$138 $132 $92 $47 $54
$120 $80 $40 $0
2002 2010 2020
$40
Direct
Indirect
Total
Diabetes Care 26:917-932, 2003
Percentage of Patients With Diabetes Having A1C <7%

Percent at goal 100 80 60
US Adults With Diagnosed Diabetes in 1988-94 NHANES III 73 45 26
40
20 0 Diet alone
38
Oral agents Therapy used
Insulin
Whole population
Harris MI, et al. Diabetes Care. 1999;22:403-408.
Lessons from the DCCT and UKPDS: Sustained Intensification of Therapy is Difficult
DCCT (Type 1)
10
9.0 8.1
EDIC
8
UKPDS (Type 2), Insulin Group
7.9 7.3
A1C (%)
A1C (%)
7
Baseline
6 4 0 6.5 +4 + 6 yrs 0 0 2 4 6
Normal
10 yrs
DCCT
EDIC
DCCT/EDIC Research Group. New Engl J Med 2000; 342:381-389 Steffes M et al. Diabetes 2001; 50 (suppl 2):A63 UK Prospective Diabetes Study Group (UKPDS) 33 Lancet 1998; 352:837-853
Relationship between % BG in Target and A1C Level

33% 18% 49% 41% 14% 45%
A1C = 7% 46%
Within Target
Above Target Below Target
A1C = 8% 42%
12%
A1C = 8.5%
Brewer K, Chase P, Owen S, Garg S, Diabetes Care 1998, 21:2.
Primary Objectives of Effective Management

A1C % 9 8 7 SBP mm Hg
145 130 Reduction of both micro- and macrovascular event rates by 75%!
Diagnosis
lGde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
LDL mg/dL
140 100 45 50 55 60 65
70
75
80
85
90
Patient Age
How is diabetes currently being treated?
Roper Starch Worldwide

Gold Standard market research study of diabetes patients 18 years and older Self reported information
Conducted annually in the U.S. N= 6,000
Roper Starch Worldwide, 2002
PROGRESSION TO INSULIN USE (US)

Among Type 2 diabetic patients sampled
Total Type 2 patients
Exclusive Insulin 15% Dual Insulin/Pill 13% Exclusive Pills 63%
Prior Therapy
43% no prior therapy 41% exclusive pills 5% diet to pills
Prior Therapy
51% exclusive pills 14% insulin 13% pills to insulin
Prior Therapy
66% no prior therapy 18% diet/no med 8% insulin
Average time on pills before moving to insulin
Average time on pills before moving to insulin
Average time on diet before moving to pills =
= 4.9 years
= 5.6 years
3.2 years
Trends Among Insulin Injectors

Conventional
Pump Therapy
54%
31%
15%
Intensive Therapy
46%
%
2001
Multiple Daily Injections
Conventional
Pump Therapy
20%
43% 37%
Intensive Therapy 57%
2002
Multiple Daily Injections
ADA Physician Reported Treatment Choices Based on aggregate responses (N=213)

Insulin Treated Patients
57% 20%
23%
23% Conventional (1-2 shots/day) 57% Intensive(3 or more shots/day) 20% Insulin Pump Therapy
ADA 2003, Physician Survey, Medtronic MiniMed
Total Patients Using Insulin Pumps

200,000
200,000
Estimated figures for 2003

162,000
150,000
100,000
43,000
81,000
50,000
26,500
0 '95 '97 '99 2001 2003
Other Possible Contributions to Intensive Management

PATIENT ATTITUDES AND BEHAVIORS
DEMOGRAPHICS (US) By education and income

EDUCATION
%
High School or less College
T1
47
51
T2
50
48
% incidence within total sample
INCOME LEVEL
< $35K
T1
$35K - $75K
> $100K
32
37
19
T2
54
26

HCPs Frequently Visited By Patients

What type of healthcare professional do you normally visit for your diabetes care?
%
100
%
100
TYPE 1
80
TYPE 2
80
60
60
40
40
20
20
Endos
GPs
Nurses
Endos
GPs
Nurses
Most Feel That They Are In Good Control

Are you satisfied with your diabetes control?
Needs improvement Good control
19 US
81
Most Patients Are Satisfied With Their Health

Satisfied with overall health 100 T1 T2
86
80 60 40 20 0
US
72
71
Self-Reported A1C Results

50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0%
4.1-5.0 5.1-6.0 6.1-7.0 7.1-8.0 8.1-9.0 9.1-10.0 10.111.0 Over 11.0 Don't Know
T1 T2
Summary
Diabetes prevalence and costs continue to grow
Lower treatment targets will likely drive the adoption of more intensive management
The use of intensive insulin management continues to grow with a notable increase in insulin pump use
A potential barrier to intensive management is patients lack of awareness and perception of good control

Diabetes Update: Facts, Trends and Observations

Uploaded by

Copyright:

Available Formats

Diabetes Update: Facts, Trends and Observations

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Diabetes Update: Facts, Trends and Observations

Uploaded by

Copyright:

Available Formats

Diabetes Update

Facts, Trends and Observations

Bruce Bode, MD, FACE Atlanta Diabetes Associates

Ultimate Goals Of Diabetes Treatment

No Long Term Diabetes Complications No Acute Diabetes Complications

Lowest Incidence of Hypoglycemia

Best Quality of Life with a Chronic Disease

Relative Risk of Progression of Diabetic Complications

Lifetime Benefits of Intensive Therapy (DCCT)

DCCT Study Group, JAMA 1996, 276:1409-1415.

DCCT Research Group, N Engl J Med 1993, 329:977986.

Lowering A1C Reduces Risk of Complications

Any diabetesrelated endpoint

Retinopathy Albuminuria at 12 years

New Targets of Intensive Diabetes Management

How Are We Doing?

U.S. Diabetes Prevalence

Costs Continue to Increase (U.S.)

$138 $132 $92 $47 $54

$120 $80 $40 $0

2002 2010 2020

Diabetes Care 26:917-932, 2003

Percentage of Patients With Diabetes Having A1C <7%

US Adults With Diagnosed Diabetes in 1988-94 NHANES III 73 45 26

Oral agents Therapy used

Harris MI, et al. Diabetes Care. 1999;22:403-408.

UKPDS (Type 2), Insulin Group

Relationship between % BG in Target and A1C Level

Primary Objectives of Effective Management

How is diabetes currently being treated?

Roper Starch Worldwide

PROGRESSION TO INSULIN USE (US)

Average time on pills before moving to insulin

Average time on pills before moving to insulin

Average time on diet before moving to pills =

Trends Among Insulin Injectors

Multiple Daily Injections

Intensive Therapy 57%

Multiple Daily Injections

Roper Starch Worldwide, 2002

ADA Physician Reported Treatment Choices Based on aggregate responses (N=213)

Total Patients Using Insulin Pumps

Estimated figures for 2003

0 '95 '97 '99 2001 2003

Other Possible Contributions to Intensive Management

DEMOGRAPHICS (US) By education and income

% incidence within total sample

% incidence within total sample

HCPs Frequently Visited By Patients

Roper Starch Worldwide, 2002

Most Feel That They Are In Good Control

% incidence within total sample

Roper Starch Worldwide, 2002

Most Patients Are Satisfied With Their Health

Roper Starch Worldwide, 2002

Self-Reported A1C Results

Roper Starch Worldwide, 2002

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.